{"id":229528,"date":"2026-01-21T21:17:21","date_gmt":"2026-01-22T03:17:21","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/01\/t-dxd-pertuzumab-earns-type-ii-application-validation-in-eu-for-her2-mbc"},"modified":"2026-01-21T21:17:21","modified_gmt":"2026-01-22T03:17:21","slug":"t-dxd-pertuzumab-earns-type-ii-application-validation-in-eu-for-her2-mbc","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/01\/t-dxd-pertuzumab-earns-type-ii-application-validation-in-eu-for-her2-mbc","title":{"rendered":"T-DXd\/Pertuzumab Earns Type II Application Validation in EU for HER2+ mBC"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/t-dxd-pertuzumab-earns-type-ii-application-validation-in-eu-for-her2-mbc.jpg\"><\/a><\/p>\n<p>The EMA has validated a Type II Variation marketing authorization application for T-DXd plus pertuzumab in first-line unresectable or metastatic HER2-positive breast cancer.<\/p>\n<p>Click for more \u27a1\ufe0f<\/p>\n<hr>\n<p>The marketing authorization was based on results from the DESTINY-Breast09 trial assessing T-DXd\/pertuzumab in first-line HER2+ metastatic breast cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The EMA has validated a Type II Variation marketing authorization application for T-DXd plus pertuzumab in first-line unresectable or metastatic HER2-positive breast cancer. Click for more \u27a1\ufe0f The marketing authorization was based on results from the DESTINY-Breast09 trial assessing T-DXd\/pertuzumab in first-line HER2+ metastatic breast cancer.<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-229528","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/229528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=229528"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/229528\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=229528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=229528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=229528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}